医学
内科学
静脉血栓栓塞
队列
回顾性队列研究
多发性骨髓瘤
入射(几何)
弗雷明翰风险评分
队列研究
前瞻性队列研究
外科
血栓形成
疾病
光学
物理
作者
Fahrettin Covut,Ramsha Ahmed,Sanchit Chawla,Frank Ricaurte,Christy Samaras,Faiz Anwer,Alex Garcia,Dana E. Angelini,Sandra Mazzoni,Beth Faiman,Jason Valent,Jack Khouri
摘要
Summary The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients with newly diagnosed MM between 2010 and 2015 at Cleveland Clinic and included 575 patients in final analysis to validate this score. The c‐statistic of the IMPEDE VTE score to predict VTE within 6 months of treatment start was 0·68 (95% CI: 0·61–0·75). The 6‐month cumulative incidence of VTE was 5·0% (95% CI: 2·1–7·9) in the low risk group, compared to 12·6% (95% CI: 8·9–16·4%) and 24·1% (95% CI: 12·2–36·1) in the intermediate and high risk groups ( P < 0·001 for both). In addition, a higher proportion of patients in the VTE cohort had ECOG performance status of ≥2 as compared to the no VTE cohort (33% vs. 16%, P = 0·001). Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not predictors of VTE. In summary, we have validated the IMPEDE VTE score in our patient cohort and our findings suggest that it can be utilized as a VTE risk stratification tool in prospective studies looking into investigating VTE prophylaxis strategies in MM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI